Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

Teva's Q3 revenue fell 2% year over year to $4.4 billion and EPS dropped 47% to $0.20, while sales of three key innovative medicines rose 33% to $1.1 billion and gross margin increased to 55.5%. Generic sales remained a drag, including a 39% decline in U.S. generic revenue to $718 million, but Teva has paid down roughly $12 billion of debt since 2019 and reached its $800 million biosimilar revenue target a year early. The article sees the turnaround as progressing, though future growth depends on new and innovative products offsetting ongoing generic declines.

Analysis

The key question is whether Teva can replace shrinking, lower-value generic sales with durable branded and biosimilar cash flows—not whether its pipeline targets are large. Rising gross margin alongside weaker revenue and sharply lower EPS is a warning that gross-margin improvement has not yet translated into near-term earnings momentum; investors should verify the contribution from operating costs, interest expense, and one-offs before underwriting leverage-driven upside.

Over the next 1–3 months, the next report should show whether growth in Austedo, Ajovy, and Uzedy can absorb further U.S. generic erosion. Over 6–18 months, Weltruza uptake and biosimilar economics matter more than headline addressable-market estimates: launches face prescribing, access, and incumbent-competition hurdles, while biosimilars can add volume yet remain exposed to price competition. This also makes Teva’s transition a competitive test for Sandoz, Viatris, and Hikma, not proof that the generic business has stabilized.

Debt reduction and refinancing improve financial flexibility, but the 2027 leverage objective depends on EBITDA and cash conversion holding up through the product transition. The ADS-to-ordinary-share change may ease access, but any technical demand is likely less durable than earnings delivery. After a strong share-price run, “cheap” on forward earnings is not persuasive unless EPS stabilizes; the main contrarian risk is that the market is extrapolating launch potential while underestimating continued generic erosion. Falsifiers: renewed declines in growth-brand sales or gross margin, further EPS deterioration, or slower debt reduction; confirmation would be sequential earnings improvement and credible launch uptake.

Key Decisions for Investors

• Do not chase the rally on pipeline potential alone. Treat TEVA as a watch/conditional long; consider entry only after the next results confirm growth-brand momentum is offsetting generic declines and margin gains are reaching operating earnings.
• Track quarterly U.S. generic revenue, sales of the three established growth brands, gross-to-operating-profit conversion, and net-debt/EBITDA. A worsening combination—especially falling brand sales with slower deleveraging—would invalidate the turnaround thesis.
• Treat Weltruza, ecopipam, and DARI as milestone-driven catalysts, not base-case revenue. Reassess after approval/access and early prescription or sales evidence; do not capitalize stated market-potential figures as realized demand.
• For relative value, compare TEVA with Sandoz, Viatris, and Hikma on generic erosion, branded growth, and cash conversion before taking a pair trade; the article does not provide enough comparable data to recommend a short leg.